Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis

Yuan, Tanwei1; Hu, Yuqing1; Zhou, Xinyi1; Yang, Luoyao1; Wang, Hui2,3,4; Li, Linghua5,6; Wang, Junfeng7,8; Qian, Han-Zhu9; Clifford, Gary M.10; Zou, Huachun1,11

2022-10-01

10.1016/j.eclinm.2022.101613

ECLINICALMEDICINE   影响因子和分区

2589-5370

["Background Non-AIDS-defining cancers (NADCs) are now becoming a rising cause of morbidity among people living with HIV (PLHIV) in the highly active antiretroviral therapy (HAART) era. We conducted a systematic review and meta-analysis to estimate the summary risk of incidence and mortality of a wide range of NADCs among PLHIV compared with the general population.","Methods This systematic review and meta-analysis was registered in the PROSPERO (registration number CRD42020222020). We searched PubMed, EMBASE, Cochrane library, and Web of Science for relevant studies published before Jan 24, 2022. Cohort or registry linkage studies comparing the incidence or mortality of individual NADCs in PLHIV with that in the general population were included. Studies simply reporting outcomes of cancer precursor lesions or combined NADCs were excluded. We calculated pooled standardised incidence (SIRs) and standardised mortality ratios (SMRs) and their 95% confidence intervals (CIs) using random-effects models, and used robust variance estimation to account for non-independence in study-level effect sizes.","Findings We identified 92 publications arising from 46 independent studies including 7 articles out of 7 studies from developing countries. Among the 40 types of NADCs investigated, all of the 20 infection-related NADCs, cancers related with human papillomavirus infection in particular, and half of the 20 non-infection-related NADCs occurred in excess in PLHIV compared with the general population. This risk pattern was consistent in most WHO regions and in both high-income and low-and middle-income countries. The increased SIRs for various NADCs were more evident among PLHIV with advanced immunodeficiency, and was explored by HIV transmission route, and use of HAART. PLHIV had increased mortality for anal cancer (SMR 124.07, 95% CI 27.31-563.72), Hodgkin lymphoma (41.03, 2.91-577.88), liver cancer (8.36, 3.86-18.11), lung cancer (3.95, 1.52-10.26), and skin melanoma (3.95, 1.28-12.2).","Interpretation PLHIV had increased incidence and mortality for a wide spectrum of NADCs. Primary prevention and effective treatment for NADCs in this population is urgently needed. Copyright (c) 2022 Published by Elsevier Ltd."]

Incidence Mortality Cancer People living with HIV Meta-analysis

SCI

英语

其他

General & Internal Medicine

Medicine, General & Internal

WOS:000916607100029

ELSEVIER

Web of Science

1.Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen 5181O7, Peoples R China
2.Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China
3.Third Peoples Hosp Shenzhen, Shenzhen, Peoples R China
4.Southern Univ Sci & Technol, Affiliated Hosp 2, Shenzhen, Peoples R China
5.Guangzhou Eighth Peoples Hosp, Infect Dis Ctr, Guangzhou, Peoples R China
6.Guangzhou Med Univ, Guangzhou, Peoples R China
7.Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
8.Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands
9.Yale Univ, Sch Publ Hlth, New Haven, CT USA
10.Int Agcy Res Canc IARC WHO, Early Detect Prevent & Infect Branch, Lyon, France
11.Univ New South Wales, Kirby Inst, Sydney, NSW, Australia

Yuan, Tanwei,Hu, Yuqing,Zhou, Xinyi,et al. Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis[J]. ECLINICALMEDICINE,2022,52.

Yuan, Tanwei.,Hu, Yuqing.,Zhou, Xinyi.,Yang, Luoyao.,Wang, Hui.,...&Zou, Huachun.(2022).Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis.ECLINICALMEDICINE,52.

Yuan, Tanwei,et al."Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis".ECLINICALMEDICINE 52(2022).